Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model.

OBJECTIVE The aim of our study was to evaluate the performance of a new blood-pool contrast agent, MS-325, in depicting regional lymph nodes when injected interstitially and in allowing the subsequent classification of the lymph nodes as normal or tumor-bearing (VX2 tumor). MATERIALS AND METHODS Six New Zealand white rabbits underwent adapted fast three-dimensional (3D) MR imaging before implantation of VX2 tumor cells in the flank and again 3 weeks after the implantation. For each imaging session, 0.5 mL of undiluted MS-325 was injected subcutaneously into both dorsal foot pads. For more than 120 min, the rabbits underwent repeated 3D MR imaging. The size of the individual lymph nodes and the amount of contrast agent uptake in the nodes were measured 5, 10, 15, 30, 60, and 120 min after the injection. After the rabbits had been sacrificed, their lymph nodes were removed and histopathologically analyzed. RESULTS. In normal as well as tumor-bearing hindlegs, the subcutaneous administration of MS-325 resulted in rapid delineation of popliteal, inguinal, iliac, and paraaortal lymph nodes. Tumor invasion into lymph nodes presented as circumscribed signal voids in the areas infiltrated by tumor, whereas the surrounding residual lymphatic tissue showed enhancement identical to that of normal nodes. CONCLUSION In addition to providing a safe means of displaying the normal lymphatic system, MS-325-enhanced 3D MR lymphography depicts direct tumor invasion in lymph nodes.

[1]  S. Ruehm,et al.  Interstitial MR lymphography with gadoterate meglumine: initial experience in humans. , 2001, Radiology.

[2]  N. deSouza,et al.  Detection of pelvic lymph node metastases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography. , 2001, AJR. American journal of roentgenology.

[3]  G. Adam,et al.  Interstitial T1-weighted MR lymphography: lipophilic perfluorinated gadolinium chelates in pigs. , 2001, Radiology.

[4]  T. Grist,et al.  Carotid MR angiography: phase II study of safety and efficacy for MS-325. , 2001, Radiology.

[5]  S. Ruehm,et al.  Interstitial MR lymphography with a conventional extracellular gadolinium-based agent: assessment in rabbits. , 2001, Radiology.

[6]  Mahfouz Ae MS-325 EPIX. , 2000 .

[7]  G. Frija,et al.  MR lymphography using iron oxide nanoparticles in rats: Pharmacokinetics in the lymphatic system after intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.

[8]  K. Campbell,et al.  Contrast agent‐enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy , 2000, Magnetic resonance in medicine.

[9]  T. Cheung,et al.  Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. , 2000, AJR. American journal of roentgenology.

[10]  N. Rofsky,et al.  Abdominal MR imaging with a volumetric interpolated breath-hold examination. , 1999, Radiology.

[11]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.

[12]  D C Peters,et al.  Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.

[13]  R. Dolan,et al.  MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.

[14]  R. Lauffer,et al.  Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. , 1997, Investigative radiology.

[15]  R. Dolan,et al.  MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. , 1996, Academic radiology.

[16]  M. Papisov,et al.  Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. , 1996, Radiology.

[17]  R. Castellino,et al.  Characterization of Reactive Versus Tumor-Bearing Lymph Nodes with Interstitial Magnetic Resonance Lymphography in an Animal Model , 1995, Investigative radiology.

[18]  R. Munker,et al.  Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases , 1995, Cancer.

[19]  G. Schmid-Schönbein,et al.  Mechanism of colloidal particle uptake into the lymphatic system: basic study with percutaneous lymphography. , 1995, Radiology.

[20]  R. Weissleder,et al.  MR Lymphography with a Lymphotropic T1‐Type MR Contrast Agent: Gd‐DTPA‐PGM , 1995, Magnetic resonance in medicine.

[21]  J. Barentsz,et al.  Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences. , 1995, AJR. American journal of roentgenology.

[22]  R Weissleder,et al.  MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.

[23]  B. I. Choi,et al.  Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. , 1994, Radiology.

[24]  M. Taupitz,et al.  Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits. , 1993, AJR. American journal of roentgenology.

[25]  M. Taupitz,et al.  Mr Lymphography Using Iron Oxide Particles , 1993, Acta radiologica.

[26]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. , 1990, Radiology.

[27]  R Weissleder,et al.  Experimental lymph node metastases: enhanced detection with MR lymphography. , 1989, Radiology.

[28]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[29]  P. Herman,et al.  Microcirculation of the lymph node with metastases. , 1976, The American journal of pathology.